A rare disease advocate, unhappy with FDA’s draft guidance outlining accelerated approval, is rallying congressional support to push for changes in the final document.
The EveryLife Foundation for Rare Diseases said FDA’s draft guidance on expedited approval programs does not address rare disease needs and does not meet the congressional intent outlined in the...